Skip to content
DataLookout
Menu

NCT07903311

Iron Repletion in Cystic Fibrosis

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Estimated absolute change in whole blood hemoglobin - ID Cohort
Timeframe: Baseline, and approximately 3 months

Secondary (20)

Estimated absolute change in whole blood hemoglobin - ID Cohort
Estimated proportion of non-anemic participants - ID Cohort
Estimated relative change in soluble transferrin receptor (sTfR) - ID Cohort
Estimated absolute change in transferrin saturation (TSAT) - ID Cohort
Estimated absolute change in serum iron - ID Cohort
Show 15 moreShow less
Estimated absolute change in serum ferritin - ID Cohort
Estimated absolute change in serum ferritin(adj-factor) - ID Cohort
Estimated absolute change in serum ferritin(adj-BRINDA) - ID Cohort
Estimated absolute change in sTfR index - ID Cohort
Estimated absolute change in whole blood red blood cell (RBC) mean corpuscular volume (MCV) - ID cohort
Estimated absolute change in 6-minute walk distance (6MWD) - ID Cohort
Estimated change in percent predicted forced expiratory volume in the first second (ppFEV1) - ID Cohort
Estimated absolute change in hand grip strength - ID Cohort
Estimated absolute change in body mass index (BMI) - ID Cohort
Estimated absolute change in fatigue severity score (FSS) - ID Cohort
Estimated absolute change in cystic fibrosis questionnaire revised (CFQ-R) - ID Cohort
Estimated absolute change in gastrointestinal symptom score (GI-SS) - ID Cohort
Time to next distal intestinal obstruction syndrome (DIOS) event - ID Cohort
Time to next pulmonary exacerbation (PEx) - ID Cohort
Adherence - ID Cohort

Arms and interventions

Iron Deficient IVExperimental

Participants enrolled in the ID Cohort will be randomized to an IV versus PO route of iron repletion in a 1:1 ratio. Participants are only randomized by route of repletion, not to a specified drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the IV route of administration.

Iron Deficient POExperimental

Participants enrolled in the ID Cohort will be randomized to an IV versus PO route of iron repletion in a 1:1 ratio. Participants are only randomized by route of repletion, not to a specified drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the PO route of administration.

Borderline Iron Deficient POExperimental

Participants enrolled in the Borderline ID Cohort will be randomized to a PO route of iron repletion versus usual care without specific assignment of iron repletion in a 1:1 ratio. Participants are not randomized to a specific drug or dose. Rather, selection of the iron repletion formulation and dose will be determined by the participant's treating clinician. This arm is randomized to the PO route of administration.

Borderline Iron Deficient Usual CareNo intervention

Participants enrolled in the Borderline ID Cohort will be randomized to a PO route of iron repletion versus usual care without specific assignment of iron repletion in a 1:1 ratio. Usual care is defined as continued clinical care as usual without a specific plan to replete iron. This arm is randomized to usual care.

Drugs: IV Repletion, PO Repletion

Sites

8 sites in 1 country